Lynparza (Olaparib)
olaparib 150 mg tablet, 56 · ORAL · PBS code 14215E
AUTHORITY_REQUIREDWhat it costs
AU$3234.75 PBS-determined price per 112 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2024-07-01.
- • Repeats: 6.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Early breast cancer
Continuing treatment
Patient must have received PBS-subsidised treatment with this drug as adjuvant therapy for this condition; AND
Patient must not have developed disease recurrence while receiving treatment with this drug for this condition; AND
The treatment must not be a PBS-subsidised benefit beyond a total of 52 weeks of treatment (including any non-PBS-subsidised supply); AND
The treatment must not in combination with any of the following: (i) abemaciclib, (ii) pembrolizumab, (iii) ribociclib; AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Sponsor: AstraZeneca Pty Ltd ABN 54 009 682 311
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.